Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 2Neuroendocrine Tumors 1Neoplasm Metastasis 1Kidney Neoplasms 1Colorectal Neoplasms 1

Interventions

Sunitinib 3Radiotherapy 3Cryosurgery 3pembrolizumab 2fludarabine phosphate 2Peripheral Blood Stem Cell Transplantation 2Nephrectomy 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2siltuximab 1avelumab 1Thalidomide 1Tacrolimus 1Suspensions 1Radiosurgery 1Radiofrequency Ablation 1Propranolol 1Powders 1PT-100 dipeptide 1Mycophenolic Acid 1Iodine 1Introns 1Interleukin-2 1Immunohistochemistry 1Genistein 1Gene Expression Profiling 1G250 monoclonal antibody 1Flow Cytometry 1Etoposide 1Docetaxel 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Kidney Neoplasms × Introns × Clear all
NCT00293527 2013-05-23

Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma

Ohio State University Comprehensive Cancer Center

Phase 2 Withdrawn
Genitourinary

Kidney Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡